Company Overview
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026. The company was founded in 2005 and is headquartered in Ness Ziona, Israel.
Why Investors Should Care
Generates a return on equity of 126.2%, reflecting efficient use of shareholder capital.
Carries low leverage with a debt-to-equity ratio of 0.03.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -95.26% |
| 6 Months: | -93.62% |
| 3 Months: | -89.64% |
| 1 Month: | -46.63% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)16.29 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 126.2%.
CONS
- Trading 95.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 16 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ENLV Enlivex Ltd. PHARMA | 1.11 | 0.00 | $19.41M | 0.00% | -0.65% | 126.17% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 4.88M | 3.50M | 3.08M | 2.56M | 5.86M |
| Operating Income | -4.88M | -3.50M | -3.08M | -2.56M | -5.86M |
| EBITDA | -4.84M | -3.41M | -2.99M | -2.48M | -5.79M |
| Interest Expense | - | - | - | - | - |
| Pretax Income | -5.18M | -3.45M | -1.87M | -2.21M | 1.63B |
| Tax Provision | - | - | - | - | - |
| Net Income | -5.18M | -3.45M | -1.87M | -2.21M | 1.24B |
| Diluted EPS | - | -0.15 | -0.08 | -0.09 | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 25.80M | 25.15M | 14.93M | 15.00M |
| Operating Income | - | -25.80M | -25.15M | -14.93M | -15.00M |
| EBITDA | - | -25.02M | -24.32M | -14.39M | -14.67M |
| Interest Expense | - | - | - | - | - |
| Pretax Income | - | -31.06M | -29.07M | -15.01M | 1.62B |
| Tax Provision | - | - | 0 | 0 | 382.65M |
| Net Income | - | -31.06M | -29.07M | -15.01M | 1.24B |
| Diluted EPS | -0.81 | -1.69 | -1.56 | -0.73 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 67.64M | 36.83M | 27.69M | 2.33B |
| Current Assets | - | 52.33M | 33.76M | 25.99M | 1.74B |
| Cash & Equivalents | - | 49.95M | 813.00K | 3.30M | 1.89M |
| Inventory | - | - | - | - | - |
| Receivables | 2.20M | - | - | - | - |
| Total Liabilities | - | 10.80M | 6.75M | 4.10M | 392.05M |
| Current Liabilities | - | 6.61M | 6.06M | 3.80M | 9.02M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 4.85M | 1.03M | 534.00K | 641.00K |
| Total Equity | - | 56.84M | 30.08M | 23.59M | 1.93B |
| Shares Outstanding | - | 18.42M | 18.60M | 23.65M | 237.38M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -23.95M | -23.52M | -13.01M | -10.42M |
| Investing Cash Flow | - | 62.52M | -25.97M | 9.06M | -1.32M |
| Financing Cash Flow | - | 150.00K | 360.00K | 6.45M | 10.38M |
| Capital Expenditure | - | -8.12M | -236.00K | -103.00K | -68.00K |
| Free Cash Flow | - | -32.08M | -23.76M | -13.11M | -10.48M |
| Net Change in Cash | - | 38.72M | -49.13M | 2.50M | -1.36M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | -54.6% | -96.6% | -63.6% | 63.9% |
| ROCE % | - | -42.3% | -81.7% | -62.5% | -0.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | ARK Investment Management, LLC | 0.91% | 158.85K | $128.13K |
| 2 | Prelude Capital Management LLC | 0.12% | 21.42K | $17.28K |
| 3 | Bank of America Corporation | 0.07% | 12.88K | $10.39K |
| 4 | Two Sigma Investments, LP | 0.07% | 12.26K | $9.89K |
| 5 | Persistent Asset Partners Ltd | 0.06% | 9.86K | $7.95K |
| 6 | Susquehanna International Group, LLP | 0.06% | 10.51K | $8.48K |
| 7 | Geode Capital Management, LLC | 0.05% | 8.66K | $6.98K |
| 8 | JPMORGAN CHASE & CO | 0.05% | 8.09K | $6.52K |
| 9 | Renaissance Technologies, LLC | 0.05% | 8.93K | $7.20K |
| 10 | Simplex Trading, LLC | 0.04% | 7.43K | $5.99K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ENLV
Enlivex investor may fund proposed $400M deal with RAIN tokens - Stock Titan
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxObDlvUEV5WTZxVy1VOVhneWZjUzhGalRuakpSMEk4WlRQQ3RaaUhEME83UFdkcHU1ZlBFUzRVNTNtV1hqeG5sbGVRS1VaU0xQaU1fZVdpS3Nyc09TWHFXNHJIU0xkVWRDVGlhQnlwT0VEVjdGclJjbExUNkR6QmFlcnhlWmVLRjFGeTFIdH…
ENLV Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE40SlpQWERpMWVQR1dOak1fUFJnYlNhbVdJNURLamJMRkE5dDByS0hxa2VsT3JrRVZyUWVEeVZKSWxRV0F6S09VV2R2RmFhV2huX1c1dW9GNnpadnZSdVVZaWEtMTlTZm1rVTlTQzNVd0ktbC1VdnFDUTVR?oc=5" target="_blank">ENL…
Enlivex Ltd. (ENLV) Upgraded to Buy: Here's Why - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxQMVg0T2diOW9sNmpJeDhmMWZNUGYyOGtNNllrN090M2xSelEtY09CTFJCQ2NTR1VpT05ySUVVSnRfc0l0SHlkWjJfc0lPM3B2TXpfYWp4VzRENDYtaWlTWDRWZXFYdWNEbi1JR0JRbl92Q2tfTWRiemI5Tjd3ZFVqZWt2cmp6dzVPTWNPdi…
ENLV - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE5VZXA1MnNwN2o5WWJUSGhjNFRLajRlWHRVVm84c3VNTURFZHJtNVhFVmFyc2kwSlJyd2J0VG1HYjUweEt2Unc?oc=5" target="_blank">ENLV</a> <font color="#6f6f6f">Finviz</font>…
ENLV Stock Slides Into 1-For-15 Reverse Split On Nasdaq - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMickFVX3lxTE1lSW9lYnpsOVRfbmwwWlFEcmJCUEpyQThJVHpuYmpKUGtpVDk4c1NPdDdsZ1o1UUhEWWJqd0huNklWTDhzczZpNTBKWHF6WE50QVBaXzlBdkhvWTBFd3EyZ2VMak1la3JGZDhwOVVkS3BMQQ?oc=5" target="_blank">ENLV Stock Sl…
H.C. Wainwright raises Enlivex stock price target to $80 on token gains - Investing.com
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxPOXNBZDFCQXBPWUlPaGE1NEVfZlIyOVVhd1lIRHpVNWRQaXRMLTR0SXlfcVpuOE5tcWQtVVFBRUZjUFNJUDhUWHlOaXNOcXdLaVdMa1c0Vkg3VDdXTnVaOTRUQ2w1ODQ1enBiUW9BOTF4dU5tZ21Xc3hHTEpULW1NZUhRaWVMSktjb2V4Yn…
ENLV — Frequently Asked Questions
What is the current share price of Enlivex Ltd. (ENLV)?
As of 2026-09-19 21:16 PDT, Enlivex Ltd. (ENLV) trades at $1.11 on NasdaqCM. Its 52-week range is $1.10 to $27.30.
What is the market capitalisation of ENLV?
Enlivex Ltd. (ENLV) has a market capitalisation of $19.41M on NasdaqCM.
What is the return on equity (ROE) of ENLV?
ENLV has a return on equity (ROE) of 126.17%. Its return on capital employed (ROCE) is -0.65%.
Is ENLV a good stock to buy?
This page provides a data-driven analysis of Enlivex Ltd. (ENLV), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.